Giannini EG, et al. - In this investigation, researchers evaluated the clinical, biochemical and instrumental outcome of patients with advanced, compensated chronic hepatitis C virus infection (HCV)-related liver disease with direct-acting antiviral (DAA)-induced sustained virological response (SVR) to DAAs and who had at least 1-year follow-up. Study participants included 52 patients with cirrhosis (n = 27) and fibrosis stage F3 (n = 25) followed up for a median of 60 weeks after successful DAA treatment. From a median baseline of 15.2 kPa to 9.3 kPa at follow-up, liver stiffness decreased. In patients with advanced chronic liver disease, liver stiffness improves significantly in the long-term after SVR and this improvement is accompanied by an improvement in indirect indices of liver fibrosis and function and a reduction in portal hypertension parameters.